• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Actuate Therapeutics Inc.

    4/6/26 4:06:56 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACTU alert in real time by email
    DEFA14A 1 actu_defa14a.htm DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement
    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐ Definitive Proxy Statement
    ☒ Definitive Additional Materials
    ☐ Soliciting Material under §240.14a-12

     

    ACTUATE THERAPEUTICS, INC.

    (Name of registrant as specified in its charter)

     

    (Name of person(s) filing proxy statement, if other than the registrant)

     

    Payment of Filing Fee (Check the appropriate box):

    ☒ No fee required.
    ☐ Fee paid previously with preliminary materials.
    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

     

     

     

     

       

     

     

     

    Your Vote Counts! *Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V87074 - P47654 ACTUATE THERAPEUTICS, INC. C/O BROADRIDGE CORPORATE ISSUER SOLUTIONS P.O. BOX 1342 BRENTWOOD, NY 11717 ACTUATE THERAPEUTICS, INC. 2026 Annual Meeting Vote by May 20, 2026 11:59 PM EDT You invested in ACTUATE THERAPEUTICS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on May 21, 2026. Get informed before you vote View the Notice and Proxy Statement and Annual Report on Form 10 - K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 7, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1 - 800 - 579 - 1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Vote Virtually at the Meeting* May 21, 2026 11:00 a.m. EDT Virtually at: www.virtualshareholdermeeting.com/ACTU2026

       

     

     

     

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. For 1. Election of Directors Nominees: 1) Aaron G. L. Fletcher, Ph.D. 2) Jason Keyes For 2. To ratify the selection of Crowe LLP, as the independent registered public accounting firm for the year ending December 31, 2026. NOTE: Such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof. Voting Items Board Recommends V87075 - P47654

       

     

    Get the next $ACTU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACTU

    DatePrice TargetRatingAnalyst
    8/26/2025$20.00Buy
    B. Riley Securities
    4/22/2025$21.00Buy
    Craig Hallum
    3/17/2025$20.00Buy
    H.C. Wainwright
    More analyst ratings

    $ACTU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bios Equity Cof, Lp bought $499,996 worth of shares (71,428 units at $7.00) (SEC Form 4)

    4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

    6/30/25 1:03:52 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kreis Leslie W. bought $499,996 worth of shares (71,428 units at $7.00) (SEC Form 4)

    4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

    6/30/25 1:02:42 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fletcher Aaron G.L. bought $499,996 worth of shares (71,428 units at $7.00) (SEC Form 4)

    4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

    6/30/25 1:01:13 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACTU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer

    - Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall survival (mOS) when treated with elraglusib plus gemcitabine/Abraxane (GnP) versus GnP alone - Patients with P53WT genomics receiving elraglusib plus GnP showed a near doubling of mOS versus GnP alone - Patients receiving elraglusib plus FOLFIRINOX demonstrated deep and sustained clinical responses and increased mOS versus FOLFIRINOX alone or in combination with losartan - Elraglusib treatment was well tolerated when used in combination with either GnP or FOLFIRINOX CHICAGO and FORT WORTH, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU), a clinical-stage bio

    6/1/26 7:00:00 AM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program

    Elraglusib oral tablet formulation to drive next-phase clinical development and broader clinical useFDA cleared IND for Phase 1/2 study of oral elraglusib in advanced cancer patients, with focus on metastatic melanoma, NSCLC, colorectal, and pancreatic cancers with initiation planned for 2H 2026Elraglusib plus RAS inhibitor preclinical results expected in mid-2026 Industry veteran Martin Huber, MD, joins Board of Directors CHICAGO and FORT WORTH, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers

    5/11/26 7:00:00 AM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors

    CHICAGO and FORT WORTH, Texas, May 06, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, today announced the appointment of Martin Huber, MD, as an Independent Director, effective immediately. This appointment strengthens Actuate's leadership team as it advances elraglusib across multiple difficult-to-treat cancer indications toward registration studies and commercialization. "We are pleased to welcome Marty to our Board of Directors. His dedication and expertise are going to prove invaluable to our mission,

    5/6/26 8:45:00 AM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACTU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Actuate Therapeutics with a new price target

    B. Riley Securities initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $20.00

    8/26/25 8:17:26 AM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Craig Hallum initiated coverage on Actuate Therapeutics with a new price target

    Craig Hallum initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $21.00

    4/22/25 8:00:39 AM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Actuate Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $20.00

    3/17/25 7:17:09 AM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACTU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Zabrowski Dan

    4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

    5/22/26 4:15:21 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Thomson Todd S

    4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

    5/22/26 4:14:24 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Sawhney Roger

    4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

    5/22/26 4:10:59 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACTU
    SEC Filings

    View All

    Actuate Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

    5/22/26 4:43:53 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Actuate Therapeutics Inc.

    S-8 - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

    5/14/26 4:06:37 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Actuate Therapeutics Inc.

    10-Q - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

    5/14/26 4:01:00 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACTU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Actuate Therapeutics Inc.

    SC 13D - ACTUATE THERAPEUTICS, INC. (0001652935) (Subject)

    8/19/24 8:59:59 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACTU
    Financials

    Live finance-specific insights

    View All

    Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

    HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as enrollment accelerates in Japan and Taiwan, where 33-40% of NSCLC cases occur in never-smokers, positioning Lantern for multiple clinical readouts in 2025. LP-184 received two U.S. FDA Fast Track Designations in 2024 for Glioblastoma and Triple Negative Breast Cancer, plus three additional Rare Pediatric Disease Designations, strengthening future market potential across multiple high-need indications with multi billion U.S. dollar market potential. Successfully dosed multiple pati

    3/27/25 4:01:00 PM ET
    $ACTU
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACTU
    Leadership Updates

    Live Leadership Updates

    View All

    Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program

    Elraglusib oral tablet formulation to drive next-phase clinical development and broader clinical useFDA cleared IND for Phase 1/2 study of oral elraglusib in advanced cancer patients, with focus on metastatic melanoma, NSCLC, colorectal, and pancreatic cancers with initiation planned for 2H 2026Elraglusib plus RAS inhibitor preclinical results expected in mid-2026 Industry veteran Martin Huber, MD, joins Board of Directors CHICAGO and FORT WORTH, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers

    5/11/26 7:00:00 AM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors

    CHICAGO and FORT WORTH, Texas, May 06, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, today announced the appointment of Martin Huber, MD, as an Independent Director, effective immediately. This appointment strengthens Actuate's leadership team as it advances elraglusib across multiple difficult-to-treat cancer indications toward registration studies and commercialization. "We are pleased to welcome Marty to our Board of Directors. His dedication and expertise are going to prove invaluable to our mission,

    5/6/26 8:45:00 AM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care